Private equity firm Bain Capital and Cinven completed the acquisition of specialty ingredients business from Lonza, a producer of organic fine chemicals, biocides, active ingredients, and biotechnology products, for $4.7bn. "Since announcing our intention to divest the Specialty Ingredients business, we have made significant progress in consolidating our new structure and identity and refining our focus as a pure-play partner to the healthcare industry. As the divestment of the Specialty Ingredients business completes, at Lonza we have an opportunity to consolidate our identity and redouble our focus on long-term growth while delivering value for our customers, employees and shareholders," Albert M. Baehny, Lonza Chairman.